文献速递腹部技术与安全PETCT

结直肠癌18F-FDG PET/CT瘤内代谢异质性参数与KRAS突变的相关性

Correlation between 18F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer.
PubMed 文献 · Abdom Radiol (NY) · 2022-02-09

研究纳入101例接受18F-FDG PET/CT及KRAS突变分析的结直肠癌患者,评估瘤内代谢异质性参数与KRAS突变状态的关系。KRAS突变组SUVmax、MTV、TLG、CV2.5、HI-2高于野生型,CV40%低于野生型,HI-1无显著差异。多因素分析显示MTV是KRAS突变的唯一显著预测因子(OR=4.97,95%CI 1.04-23.83,p=0.045),截断值7.62时AUC=0.695,敏感度90.2%、特异度45.0%。

要点

  • KRAS突变组SUVmax、MTV、TLG及异质性参数CV2.5、HI-2高于野生型组。
  • MTV是KRAS突变的唯一独立预测因子,截断值7.62时AUC=0.695。
  • MTV预测KRAS突变敏感度90.2%、特异度45.0%,特异度偏低。

核心结论

  • KRAS突变型结直肠癌患者较野生型有更高的18F-FDG摄取(SUVmax、MTV、TLG)和异质性(CV2.5、HI-2),MTV是KRAS基因突变的唯一独立预测因子。

研究设计与样本

  • 研究纳入101例接受18F-FDG PET/CT及KRAS突变分析的结直肠癌患者,获取原发灶的SUVmax、MTV、TLG及异质性参数CV2.5、CV40%、HI-1、HI-2,分析其与KRAS突变状态的相关性。

诊断标准与关键数值

  • KRAS突变组与野生型组比较:SUVmax 19.00 vs 13.16(p<0.001),MTV 11.64 vs 8.83(p=0.001),TLG 102.85 vs 69.76(p<0.001),CV2.5 0.55 vs 0.46(p=0.006),HI-2 14.03 vs 7.59(p<0.001),CV40% 0.22 vs 0.24(p=0.001,突变组较低),HI-1两组无显著差异。

临床应用与阅片要点

  • 多因素分析显示MTV是KRAS突变的唯一显著预测因子(OR=4.97,95%CI 1.04-23.83,p=0.045),截断值7.62时AUC=0.695,敏感度90.2%、特异度45.0%;但PET参数并非KRAS突变的独立预测因子。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The study aimed to evaluate the relationship between intra-tumor metabolic heterogeneity parameters of 18F-FDG and KRAS mutation status in colorectal cancer (CRC) patients and which threshold heterogeneity parameters could better reflect the heterogeneity characteristics of colorectal cancer.

METHODS: Medical data of 101 CRC patients who underwent 18F-FDG PET/CT and KRAS mutation analysis were selected. On PET scans, 18F-FDG traditional indices maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity parameters coefficient of variation with a threshold of 2.5 (CV2.5), CV40%, heterogeneity index-1 (HI-1), and HI-2 of the primary lesions were obtained. We inferred correlations between these 18F-FDG parameters and KRAS mutation status.

RESULTS: 41 patients (40.6%) had KRAS gene mutation. Assessment of FDG parameters showed that SUVmax (19.00 vs. 13.16, p < 0.001), MTV (11.64 vs. 8.83, p = 0.001), and TLG (102.85 vs. 69.76, p < 0.001), CV2.5 (0.55 vs. 0.46, p = 0.006), and HI-2 (14.03 vs. 7.59, p < 0.001) of KRAS mutation were higher compared to wild-type (WT) KRAS. CV40% (0.22 vs. 0.24, p = 0.001) was lower in the KRAS mutation group, while HI-1 had no significant difference between the two groups. Multivariate analysis showed that MTV (OR = 4.97, 1.04-23.83, p = 0.045) was the only significant predictor in KRAS mutation, using a cut-off of 7.62 (AUC = 0.695), and MTV showed a sensitivity of 90.2% and specificity of 45.0%. However, the PET parameters were not independent predictors in KRAS mutation.

CONCLUSION: KRAS gene mutant CRC patients had more 18F-FDG uptake (SUVmax, MTV, TLG) and heterogeneity (CV2.5, HI-2) than WT KRAS. MTV was the only independent predictor of KRAS gene mutation in colorectal cancer patients.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Liu, Wang, Ni, et al. Correlation between 18F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer. Abdom Radiol (NY). 2022. PMID: 35138462. doi:10.1007/s00261-022-03432-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。